医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Acidic/hypoxia dual-alleviated nanoregulators for enhanced treatment of tumor chemo-immunotherapy

摘要Chemotherapy plays a crucial role in triple-negative breast cancer(TNBC)treatment as it not only directly kills cancer cells but also induces immunogenic cell death.However,the chemotherapeutic efficacy was strongly restricted by the acidic and hypoxic tumor environment.Herein,we have successfully formulated PLGA-based nanoparticles concurrently loaded with doxorubicin(DOX),hemoglobin(Hb)and CaCO3 by a CaCO3-assisted emulsion method,aiming at the effective treatment of TNBC.We found that the obtained nanomedicine(DHCaNPs)exhibited effective drug encapsulation and pH-responsive drug release behavior.Moreover,DHCaNPs demonstrated robust capabilities in neutralizing protons and oxygen transport.Consequently,DHCaNPs could not only serve as oxygen nanoshuttles to attenuate tumor hypoxia but also neutralize the acidic tumor microenvironment(TME)by depleting lactic acid,thereby effectively overcoming the resistance to chemotherapy.Furthermore,DHCaNPs demonstrated a notable ability to enhance antitumor immune responses by increasing the frequency of tumor-infiltrating effector lymphocytes and reducing the frequency of various immune-suppressive cells,therefore exhibiting a superior efficacy in suppressing tumor growth and metastasis when combined with anti-PD-L1(αPD-L1)immunotherapy.In summary,this study highlights that DHCaNPs could effectively attenuate the acidic and hypoxic TME,offering a promising strategy to figure out an enhanced chemo-immunotherapy to benefit TNBC patients.

更多
广告
作者 Xiaoju Guo [1] Xiaoxiao Chen [2] Jiayi Ding [3] Feng Zhang [3] Shunyang Chen [1] Xin Hu [1] Shiji Fang [4] Lin Shen [3] Chenying Lu [5] Zhongwei Zhao [5] Jianfei Tu [5] Gaofeng Shu [2] Minjiang Chen [2] Jiansong Ji [5] 学术成果认领
作者单位 Lishui Central Hospital,Shaoxing University,Shaoxing 312000,China;Zhejiang Key Laboratory of Imaging and Interventional Medicine,Imaging Diagnosis and Interventional Minimally Invasive Institute,The Fifth Affiliated Hospital of Wenzhou Medical University,Lishui 323000,China [1] Zhejiang Key Laboratory of Imaging and Interventional Medicine,Imaging Diagnosis and Interventional Minimally Invasive Institute,The Fifth Affiliated Hospital of Wenzhou Medical University,Lishui 323000,China;Key Laboratory of Precision Medicine of Lishui,Lishui 323000,China [2] Zhejiang Key Laboratory of Imaging and Interventional Medicine,Imaging Diagnosis and Interventional Minimally Invasive Institute,The Fifth Affiliated Hospital of Wenzhou Medical University,Lishui 323000,China [3] Zhejiang Key Laboratory of Imaging and Interventional Medicine,Imaging Diagnosis and Interventional Minimally Invasive Institute,The Fifth Affiliated Hospital of Wenzhou Medical University,Lishui 323000,China;Clinical College of The Affiliated Central Hospital,School of Medicine,Lishui University,Lishui 323000,China [4] Lishui Central Hospital,Shaoxing University,Shaoxing 312000,China;Zhejiang Key Laboratory of Imaging and Interventional Medicine,Imaging Diagnosis and Interventional Minimally Invasive Institute,The Fifth Affiliated Hospital of Wenzhou Medical University,Lishui 323000,China;Clinical College of The Affiliated Central Hospital,School of Medicine,Lishui University,Lishui 323000,China;Key Laboratory of Precision Medicine of Lishui,Lishui 323000,China [5]
栏目名称
DOI 10.1016/j.ajps.2024.100905
发布时间 2024-09-03(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览2
  • 下载0
亚洲药物制剂科学(英文版)

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷